(Q36133754)

12 August 2017

Completion of the human papillomavirus vaccine series among insured females between 2006 and 2009 (English)

1 reference

12 August 2017

1 reference

4

Abbey B Berenson

1 reference

12 August 2017

Jacqueline M Hirth

1

1 reference

12 August 2017

Alai Tan

series ordinal

2

1 reference

12 August 2017

Gregg S Wilkinson

series ordinal

3

1 reference

12 August 2017

language of work or name

English

0 references

publication date

27 April 2012

1 reference

12 August 2017

1 reference

12 August 2017

118

1 reference

12 August 2017

22

1 reference

12 August 2017

5623-5629

1 reference

Cervical adenocarcinoma: moving towards better prevention

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3410047

End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3410047

Human papillomavirus (HPV) vaccine uptake and completion at an urban hospital

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3410047

Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3410047

Correlates for completion of 3-dose regimen of HPV vaccine in female members of a managed care organization

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3410047

Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3410047

Prevalence of HPV infection among females in the United States

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3410047

Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3410047

Fertility, family planning, and reproductive health of U.S. women: data from the 2002 National Survey of Family Growth

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3410047

Patient reminder and recall systems to improve immunization rates

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3410047

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3410047

The HPV vaccine: are dosing recommendations being followed?

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3410047

HPV vaccine against anal HPV infection and anal intraepithelial neoplasia

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3410047

National and state vaccination coverage among adolescents aged 13 through 17 years--United States, 2010.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3410047

Impact of vaccinating boys and men against HPV in the United States

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3410047

Factors associated with completion of the human papillomavirus vaccine series

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3410047

A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions

23 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCNCR.27598

Incremental Impact of Adding Boys to Current Human Papillomavirus Vaccination Programs: Role of Herd Immunity

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCNCR.27598

Vaccination coverage and physician distribution in the United States, 1997

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22544681

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Text message reminders to promote human papillomavirus vaccination

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22544681

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1002/CNCR.27598

1 reference

12 August 2017

1 reference

12 August 2017

PubMed publication ID

22544681

1 reference